Repositioning and rethinking
New approaches to care for difficult-to-treat diseases
Repositioning and Rethinking
New approaches to care for difficult-to-treat diseases
Who are we
Reponex Pharmaceuticals is a dedicated company focused on rethinking and repositioning existing drugs to address difficult-to-treat diseases. Our team is committed to leveraging scientific advancements to innovate and enhance therapeutic solutions. We collaborate closely with academic and industry partners to fulfill our mission of developing effective treatments that make a meaningful difference in patient care.
In February 2023, Pharma Equity Group, the parent company of Reponex, approved its transaction with us. Pharma Equity Group is publicly traded on the Nasdaq Copenhagen Stock Exchange and is committed to supporting Reponex Pharmaceuticals’ growth and success. The group collaborates with us, utilizing the expertise of its professionals in life sciences, investment, and business development.
Reponex Pharmaceuticals A/S is dedicated to developing new, effective treatments for diseases that significantly impact patients and society, particularly where current therapies are lacking or require improvement. Our focus encompasses acute and life-threatening conditions, such as bacterial peritonitis and colorectal cancer, as well as chronic diseases that reduce quality and length of life, including inflammatory bowel diseases and complications of chronic conditions, like non-healing skin ulcers in patients with diabetes or venous insufficiency. We aim to address the ongoing unmet medical needs associated with these challenging conditions.
Our Business Model
It is Reponex’s ambition to create value through the company’s sustaining platform by bringing the clinical programs to a clinical phase II stage with securing IP at which the effects of the drug candidates can be documented with relevant clinical data.
Reponex is an organizational efficient company with an aggressive commercial outsourcing strategy to be as agile as possible, to meet complex and continual changes in the pharma industry. The strategy creates a cost efficient and flexible way to create relevant humane ressources fast, which is considered a key factor and drives success.
Reponex drug development is based on a combination of:
- Repositioning existing APIs (active pharmaceutical ingredients).
- Clinical development strategy
- Regulatory development strategy
- Patent protection (IP)
- Outsourcing
Repositioning
Repositioning is essentially finding a new use for an established drug. Characteristically this entails using the drug for a different indication (i.e. for treating another disease) than it was initially developed for, with the advantage of opening up a new market while saving on the preclinical and clinical phase I developing costs. A simple rerouting of this type has become a standard strategy employed by established pharmaceutical companies to extend their pipeline.
Rerouting
In essence, Reponex reformulates the active pharmaceutical ingredients to make them suitable for local administration at the site where they need to act, thus avoiding conventional systemic administration such as intravenous or subcutaneous injection. This significantly enhances the drug’s efficacy, allowing it to reach its site of action at a high concentration, while simultaneously reducing or eliminating any systemic adverse reactions caused by drugs that poorly penetrate or do not penetrate at all from the site of action to the systemic circulation.
Recombining
Combining different drugs that act on different aspects of the disease pathology to achieve an additive or synergistic effect. At the same time, it is convenient for both the patient and the clinician having to apply several different medications at once to treat a single condition, using the preparation that has been developed to provide the optimal treatment. This principle is particularly well known in the drug combinations used to treat metabolic diseases, respiratory diseases and high blood pressure.
